The Association Between the Occurrence of Common Treatment-Emergent Adverse Events and Efficacy Outcomes After Lasmiditan Treatment of a Single Migraine Attack: Secondary Analyses from Four Pooled Randomized Clinical Trials

BACKGROUND: In controlled clinical trials, compared with placebo, a significantly greater proportion of participants using lasmiditan to treat a migraine attack achieved 2-h pain freedom (PF) and experienced ≥ 1 treatment-emergent adverse event (TEAE). OBJECTIVE: To better inform clinicians about tr...

Descripción completa

Detalles Bibliográficos
Autores principales: Doty, Erin G., Hauck, Paula M., Krege, John H., Komori, Mika, Hake, Ann M., Dong, Yan, Lipton, Richard B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9259541/
https://www.ncbi.nlm.nih.gov/pubmed/35779194
http://dx.doi.org/10.1007/s40263-022-00928-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9259541/
https://www.ncbi.nlm.nih.gov/pubmed/35779194
http://dx.doi.org/10.1007/s40263-022-00928-y

Ejemplares similares